By Josh Beckerman
Lifeward shares were higher as the medical device company received Food and Drug Administration 510(k) clearance for the ReWalk 7, the newest version of its personal exoskeleton product.
The stock was recently up 37% to $2.01, with an intraday range of $1.67 to $2.95. Volume was more than 95.5 million shares, compared with a 65-day average of 764,405.
The ReWalk is a motorized device that aids movement for some people with lower body paralysis.
Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare coverage.
The company formerly known as ReWalk Robotics has been working to reduce operating losses, with moves including closing two U.S. facilities.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 13, 2025 12:58 ET (16:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。